<?xml version="1.0"?>
<!DOCTYPE TimeML SYSTEM "TimeML.dtd">
<TimeML>
Novartis AG (NYSE:NVS) – Leerink Swann upped their Q1 2017 earnings per share (EPS) estimates for shares of Novartis AG in a research report issued to clients and investors on <TIMEX3 tid="t2" type="DATE" value="2017-01-26">Thursday</TIMEX3>. Leerink Swann analyst S. Fernandez <TIMEX3 tid="t5" type="DATE" value="PRESENT_REF">now</TIMEX3> anticipates that the brokerage will post earnings of $1.15 per share for <TIMEX3 tid="t4" type="DATE" value="2017-Q1">the quarter</TIMEX3>, up from their previous forecast of $1.14. Leerink Swann also issued estimates for Novartis AG’s Q2 2017 earnings at $1.22 EPS, Q3 2017 earnings at $1.25 EPS, Q4 2017 earnings at $1.29 EPS and FY2021 earnings at $6.36 EPS. 

Several other research analysts also <TIMEX3 tid="t12" type="DATE" value="PAST_REF">recently</TIMEX3> commented on NVS. Chardan Capital reduced their price target on shares of Novartis AG from $95.00 to $92.00 and set a “buy” rating on the stock in a research note on <TIMEX3 tid="t15" type="DATE" value="2017-10-10">Monday, October 10th</TIMEX3>. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Novartis AG in a research note on <TIMEX3 tid="t19" type="DATE" value="2016-10-10">Monday, October 10th</TIMEX3>. Jefferies Group LLC reaffirmed a “buy” rating on shares of Novartis AG in a research note on <TIMEX3 tid="t23" type="DATE" value="2016-10-16">Sunday, October 16th</TIMEX3>. Societe Generale reissued a “hold” rating on shares of Novartis AG in a research report on <TIMEX3 tid="t27" type="DATE" value="2016-10-27">Thursday, October 27th</TIMEX3>. Finally, Argus raised shares of Novartis AG from a “hold” rating to a “buy” rating and set a $85.00 target price on the stock in a research report on <TIMEX3 tid="t31" type="DATE" value="2017-11-10">Thursday, November 10th</TIMEX3>. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $85.18.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by sleekmoney and is the sole property of of sleekmoney. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be accessed at http://sleekmoney.com/research-analysts-offer-predictions-for-novartis-ags-q1-<TIMEX3 tid="t34" type="DATE" value="2017">2017</TIMEX3>-earnings-nvs/<TIMEX3 tid="t33" type="DATE" value="1630-10-6">1630106</TIMEX3>.html. 

Novartis AG (NYSE:NVS) opened at 72.21 on <TIMEX3 tid="t35" type="DATE" value="2017-01-27">Friday</TIMEX3>. The stock’s <TIMEX3 tid="t38" type="DURATION" value="P50D">50 day</TIMEX3> moving average is $71.89 and its <TIMEX3 tid="t39" type="DURATION" value="P200D">200 day</TIMEX3> moving average is $76.07. Novartis AG has a <TIMEX3 tid="t40" type="DURATION" value="P1Y">12-month</TIMEX3> low of $66.93 and a <TIMEX3 tid="t41" type="DURATION" value="P1Y">12-month</TIMEX3> high of $83.58. The stock has a market capitalization of $171.50 billion, a PE ratio of 25.79 and a beta of 0.68. Novartis AG (NYSE:NVS) last issued its earnings results on <TIMEX3 tid="t44" type="DATE" value="2017-01-25">Wednesday, January 25th</TIMEX3>. The company reported $1.12 earnings per share (EPS) for <TIMEX3 tid="t46" type="DATE" value="2017-Q1">the quarter</TIMEX3>, hitting the consensus estimate of $1.12. Novartis AG had a net margin of 13.80% and a return on equity of 15.46%. The firm had revenue of $12.32 billion for <TIMEX3 tid="t47" type="DATE" value="2017-Q1">the quarter</TIMEX3>, compared to the consensus estimate of $12.44 billion. During the same quarter in the prior year, the firm posted $1.14 earnings per share. The business’s revenue was down 1.6% on a year-over-year basis. 

ILLEGAL ACTIVITY WARNING: This piece of content was first published by sleekmoney and is the sole property of of sleekmoney. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be accessed at http://sleekmoney.com/research-analysts-offer-predictions-for-novartis-ags-q1-<TIMEX3 tid="t52" type="DATE" value="2017">2017</TIMEX3>-earnings-nvs/<TIMEX3 tid="t51" type="DATE" value="1630-10-6">1630106</TIMEX3>.html. 

A number of hedge funds have <TIMEX3 tid="t53" type="DATE" value="PAST_REF">recently</TIMEX3> added to or reduced their stakes in the company. WFG Advisors LP boosted its stake in Novartis AG by 8.9% in <TIMEX3 tid="t54" type="DATE" value="2016-Q2">the second quarter</TIMEX3>. WFG Advisors LP <TIMEX3 tid="t55" type="DATE" value="PRESENT_REF">now</TIMEX3> owns 1,624 shares of the company’s stock worth $134,000 after buying an additional 133 shares during the period. Mosaic Family Wealth LLC boosted its stake in Novartis AG by 11.2% in <TIMEX3 tid="t56" type="DATE" value="2016-Q3">the third quarter</TIMEX3>. Mosaic Family Wealth LLC <TIMEX3 tid="t57" type="DATE" value="PRESENT_REF">now</TIMEX3> owns 1,886 shares of the company’s stock worth $149,000 after buying an additional 190 shares during the period. First PREMIER Bank boosted its stake in Novartis AG by 65.7% in <TIMEX3 tid="t58" type="DATE" value="2016-Q3">the third quarter</TIMEX3>. First PREMIER Bank <TIMEX3 tid="t59" type="DATE" value="PRESENT_REF">now</TIMEX3> owns 1,955 shares of the company’s stock worth $154,000 after buying an additional 775 shares during the period. Integrated Wealth Counsel LLC boosted its stake in Novartis AG by 13.8% in <TIMEX3 tid="t60" type="DATE" value="2016-Q3">the third quarter</TIMEX3>. Integrated Wealth Counsel LLC <TIMEX3 tid="t61" type="DATE" value="PRESENT_REF">now</TIMEX3> owns 1,998 shares of the company’s stock worth $158,000 after buying an additional 242 shares during the period. Finally, Chicago Partners Investment Group LLC bought a new stake in Novartis AG during <TIMEX3 tid="t62" type="DATE" value="2016-Q3">the third quarter</TIMEX3> worth approximately $158,000. Institutional investors own 9.84% of the company’s stock. 

Novartis AG Company Profile

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.
</TimeML>
